Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardClinical Forum InsightsInsightsMedcastPeers & PerspectivesShorts
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Perioperative Treatment in MIBC: When to Refer and What to Expect

EP. 1: The MIBC Referral Gap: Why Half of Patients Miss Perioperative Therapy

ByJoshua J. Meeks, MD, PhD
July 31st 2026

Half of patients with MIBC never make it to perioperative therapy. In this video, Joshua J. Meeks, MD, PhD, unpacks the referral barriers behind that gap.

Advertisement
Advertisement

Trending on Urology Times

1

Testosterone deficiency: FAQs from the AUA guideline

2

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

3

From hype to practice: Urologists assess AI's real impact

4

PTEN Testing Strategies for Newly Diagnosed mHSPC

5

Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us